Kairos Pharma Ltd

Kairos Pharma operates with a negative net equity of $2.65 million and a total liabilities of $3.68 million, indicating a highly leveraged and capital-intensive structure. The company's liquidity position is weak, as reflected in a current ratio of 0.01, suggesting limited ability to meet short-term obligations. The debt-to-equity ratio is -0.29, which implies that the company's liabilities exceed its equity, further highlighting the financial strain. Profitability metrics are negative, with a net loss of $253,000 and an operating loss of $222,000. The return on equity is 9.53%, which is unusually high given the negative equity, and the return on assets is -24.56%, indicating poor asset utilization. These figures are below the typical performance of companies in the biotechnology industry, which often experience early-stage losses before commercialization. The company's revenue is reported as $0, suggesting it is in the pre-revenue phase, likely in clinical development or regulatory approval stages. There is no disclosed geographic revenue concentration, but as a pre-revenue biotech firm, its operations are likely centered in the United States, with potential clinical trials in other regions. The lack of revenue diversification across segments or geographies increases its exposure to market and regulatory risks. Looking ahead, the company is expected to continue incurring losses, with no revenue reported in the current fiscal year. The outlook for the next fiscal year is uncertain, as the company has not provided specific revenue projections. The absence of revenue and the ongoing net losses suggest a challenging growth trajectory, with the company relying on external financing to fund operations. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, signaling potential difficulties in maintaining operations without additional capital. The dilution risk is low, but the company may need to issue new shares to raise capital, which could affect shareholder value. Recent events include the continued development of KP-1019, with no significant clinical or regulatory milestones reported in the latest filings. The company has not disclosed any major partnerships or collaborations, and its financial disclosures indicate a reliance on equity financing to sustain operations. The absence of recent positive developments may impact investor sentiment and the company's ability to attract further investment.